0001209191-18-043567.txt : 20180720
0001209191-18-043567.hdr.sgml : 20180720
20180720200023
ACCESSION NUMBER: 0001209191-18-043567
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180719
FILED AS OF DATE: 20180720
DATE AS OF CHANGE: 20180720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SLATTERY JOSEPH P
CENTRAL INDEX KEY: 0001246530
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19437
FILM NUMBER: 18963370
MAIL ADDRESS:
STREET 1: C/O TRANSENTERIX, INC.
STREET 2: 635 DAVIS DRIVE, SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TRANSENTERIX INC.
CENTRAL INDEX KEY: 0000876378
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 112962080
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 635 DAVIS DRIVE
STREET 2: SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
BUSINESS PHONE: 919-765-8400
MAIL ADDRESS:
STREET 1: 635 DAVIS DRIVE
STREET 2: SUITE 300
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER COMPANY:
FORMER CONFORMED NAME: SafeStitch Medical, Inc.
DATE OF NAME CHANGE: 20080211
FORMER COMPANY:
FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC
DATE OF NAME CHANGE: 19930328
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-07-19
0
0000876378
TRANSENTERIX INC.
TRXC
0001246530
SLATTERY JOSEPH P
C/O TRANSENTERIX, INC.
635 DAVIS DRIVE, SUITE 300
MORRISVILLE
NC
27560
0
1
0
0
EVP and CFO
Common Stock
2018-07-19
4
S
0
56622
5.00
D
0
D
Common Stock
2018-07-19
4
M
0
8458
1.42
A
8458
D
Common Stock
2018-07-19
4
M
0
2083
2.45
A
10541
D
Common Stock
2018-07-19
4
M
0
5625
2.94
A
16166
D
Common Stock
2018-07-19
4
M
0
6875
3.82
A
23041
D
Common Stock
2018-07-19
4
M
0
9736
3.94
A
32777
D
Common Stock
2018-07-19
4
M
0
34999
4.02
A
67776
D
Common Stock
2018-07-19
4
S
0
67776
5.00
D
0
D
Common Stock
25000
I
By IRA
Stock Options
1.42
2018-07-19
4
M
0
8485
0.00
D
2027-02-02
Common Stock
8458
262209
D
Stock Options
2.45
2018-07-19
4
M
0
2083
0.00
D
2025-10-28
Common Stock
2083
33334
D
Stock Options
2.94
2018-07-19
4
M
0
5625
0.00
D
2025-02-04
Common Stock
5625
39376
D
Stock Options
3.82
2018-07-19
4
M
0
6875
0.00
D
2026-02-12
Common Stock
6875
130625
D
Stock Options
3.94
2018-07-19
4
M
0
9736
0.00
D
2024-05-27
Common Stock
9736
0
D
Stock Options
4.02
2018-07-19
4
M
0
34999
0.00
D
2024-04-21
Common Stock
34999
465001
D
The transaction occurred pursuant to a written trading plan dated November 29, 2017 meeting the requirements of Rule 10b5-1(c).
The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.035 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.005 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Following the sales on July 19, 2018, the reporting person continues to beneficially own 25,000 shares of the company's common stock. The reporting person also holds stock options to acquire 1,819,045 shares of common stock, of which approximately 26% are vested, and restricted stock units representing an additional 595,777 shares of common stock subject to forfeiture restrictions.
Vests 25% on the first anniversary of the date of grant and 1/48th of the entire award monthly on the vesting date anniversary for 36 months, subject to acceleration as set forth in the Incentive Plan.
Previously vested.
/s/ Joshua Weingard, as Attorney-in-Fact for Joseph Slattery
2018-07-20